Indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive breast cancer. HER2 expression must be present for initiation of Perjeta (Pertuzumab) using FDA-approved test.
Perjeta (Pertuzumab) is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of Perjeta (Pertuzumab) in a single agent setting had suggested clinical activity - including stable disease - in heavily pretreated patients with advanced ovarian and breast cancers.
Perjeta (Pertuzumab) is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
Before you receive this medication, you may need to undergo a biopsy to make sure Perjeta (Pertuzumab) is the right medication to treat your cancer.
Perjeta (Pertuzumab) is usually given once every 3 weeks. Follow your doctor's instructions.
Some side effects may occur during the injection. Tell your caregiver right away if you feel weak, tired, or nauseated, or if you have a fast heartbeat, headache, fever, chills, muscle pain, or an unusual taste in your mouth.
Get emergency medical help if you have any of these signs of an allergic reaction to Perjeta (Pertuzumab): hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Perjeta (Pertuzumab) is handled and stored by a health care provider. Keep Perjeta (Pertuzumab) out of the reach of children and away from pets.
Perjeta (Pertuzumab) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.